IR Banner

Press Releases

Date Title and Summary Additional Format
Sep 26, 2022
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
AUSTIN, Texas , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will
Aug 31, 2022
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
AUSTIN, Texas , Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host
Aug 16, 2022
Lumos Pharma Announces Share Repurchase Program
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas , Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth
Aug 9, 2022
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial -- -- Cash Runway into Second Quarter 2024 -- AUSTIN,
Jul 27, 2022
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
AUSTIN, Texas , July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022 . The company will host a conference call and
Jul 26, 2022
CEO Update: Interview with Lumos Pharma’s Chief Medical Officer, David B. Karpf, M.D.
Lumos Pharma CMO, David B. Karpf, M.D., walks us through his background and perspective on LUM-201. Q: When did you know you wanted to go into medicine – what drove you to that profession? A: My dad was an exceptional doctor, so I knew at age 5 that I wanted to be a physician.
May 16, 2022
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event: H.C.
May 10, 2022
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration Initiated with Massachusetts General
May 5, 2022
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare
Apr 26, 2022
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
AUSTIN, Tex. , April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022 . The company will host a conference call and webcast
Displaying 1 - 10 of 61